샘플 요청 목록

 카트 문의
시장보고서
상품코드
1579689

세계의 Drug Discovery 서비스 시장

Drug Discovery Services
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 89 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 Drug Discovery 서비스 시장은 2030년까지 611억 달러에 달할 것으로 전망

2023년 486억 달러로 추정되는 세계 Drug Discovery 서비스 시장은 2023-2030년간 연평균 3.3% 성장하여 2030년에는 611억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 제약 화학 서비스는 CAGR 4.0%를 기록하여 분석 기간 종료 시점에 316억 달러에 도달할 것으로 예상됩니다. 생물학 서비스 분야의 성장률은 분석 기간 동안 CAGR 2.8%로 추정됩니다.

미국 시장은 129억 달러로 추정, 중국은 CAGR 6.9%로 성장 전망

미국의 Drug Discovery 서비스 시장 규모는 2023년 129억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 141억 달러 규모에 도달할 것으로 예상되며, 2023-2030년간 6.9%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 0.8%와 1.5%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 1.4%의 성장률을 보일 것으로 예상됩니다.

세계 Drug Discovery 서비스 시장 - 주요 동향 및 촉진요인 요약

Drug Discovery 서비스는 어떻게 의약품 연구개발을 가속화하고 있는가?

신약 개발 서비스는 의약품 개발의 중요한 단계를 전문 서비스 제공업체에 아웃소싱하여 속도, 효율성 및 비용 효율성을 향상시킴으로써 의약품 연구 및 개발(R& D)을 변화시키고 있습니다. 이러한 서비스 제공업체(대부분 CRO)는 고처리량 스크리닝, 후보물질 발굴, 전임상 연구, 임상시험 등의 분야에서 전문성을 제공함으로써 제약사가 외부 역량을 활용하면서 핵심 역량에 집중할 수 있도록 돕고 있습니다. 초기 단계의 연구개발을 아웃소싱함으로써 기업은 유망한 신약 후보물질을 신속하게 발굴하고 임상시험에 진입할 수 있습니다.

신약 개발 프로세스를 가속화하는 것 외에도, CRO는 제약사가 고비용, 규제 문제, 고도의 기술 요건 등 현대 R&D의 복잡성을 극복할 수 있도록 돕고, 차세대 시퀀싱, 단백질체학, 바이오인포매틱스와 같은 첨단 기술에 대한 접근성을 제공하여 데이터 집약적인 연구와 타겟팅된 의약품 개발을 지원합니다. 데이터 집약적 연구와 표적화된 의약품 개발을 지원합니다. 이 파트너십 모델은 대규모 사내 R&D 부서를 운영할 자원이 없으면서도 혁신을 추진하고 시장에서 경쟁하고자 하는 중소규모의 생명공학 기업에게 특히 유용합니다.

Drug Discovery 서비스에서 기술의 역할은 무엇인가?

인공지능(AI), 머신러닝, 바이오인포매틱스, 하이스루풋 스크리닝의 발전으로 기술은 Drug Discovery 서비스의 역량과 효율성을 높이는 데 있어 매우 중요한 역할을 하고 있으며, AI와 머신러닝 알고리즘을 통해 CRO는 대규모 데이터 세트를 분석하고 잠재적 약물 후보를 식별하고, 화합물의 상호작용을 예측하고, 표적 특이성 및 효능을 기반으로 리드 화합물을 최적화할 수 있습니다. 하이스루풋 스크리닝 기술은 생물학적 표적에 대한 수천 개의 화합물을 신속하게 테스트할 수 있어 신약 개발 과정의 초기 단계에서 유망한 후보 화합물을 식별하고 R&D 단계의 진행을 가속화할 수 있습니다.

또한, 계산 모델링 및 시뮬레이션 기술은 임상시험에 들어가기 전에 약물 후보물질의 약동학적 특성과 잠재적 독성을 예측하여 비용이 많이 드는 후기 단계의 실패를 줄일 수 있도록 도와줍니다. 생물정보학 및 분자생물학 도구는 유전자 및 단백질 데이터 분석을 통해 보다 정확한 약물 타겟팅을 가능하게 합니다. 이러한 혁신을 통해 Drug Discovery 서비스 제공업체는 고도의 연구 역량을 갖추고 더 안전하고 효과적인 의약품을 더 빨리, 더 효율적으로 시장에 출시하려는 제약사의 사명을 지원하고 있습니다.

제약회사가 Drug Discovery 서비스를 이용하게 된 이유

제약사들은 연구개발의 효율성을 최적화하고, 전문지식을 활용하고, 자체 개발 비용을 절감하기 위해 Drug Discovery 서비스에 대한 의존도를 높이고 있습니다. R&D 인프라를 유지하기 위해서는 전문 연구인력 고용, 연구장비 투자 등 고정비용이 많이 들기 때문에 아웃소싱이 현실적인 선택이 되고 있습니다. Drug Discovery 서비스를 통해 제약회사는 표적 발굴부터 전임상시험까지 개발의 각 단계에서 전문 지식을 주문형으로 활용할 수 있으며, 프로젝트의 필요와 시장 수요에 따라 R&D 자원을 유연하게 조정할 수 있습니다.

또한, Drug Discovery 서비스 제공업체는 종양학, 면역학, 중추신경계 질환과 같은 틈새 분야의 전문성을 제공함으로써 제약사가 혁신적인 연구 방법론과 지식에 접근할 수 있도록 돕습니다. 이러한 서비스 제공업체는 규제 가이드라인을 최신 상태로 유지하여 기업이 임상시험 요건과 컴플라이언스 규제를 효율적으로 통과할 수 있도록 지원합니다. 전문 서비스 제공업체에 아웃소싱함으로써 기업은 리스크 관리를 강화하고 시장 출시 시간을 단축하며 전략적 우선순위에 집중할 수 있습니다.

Drug Discovery 서비스 시장의 성장 원동력은?

Drug Discovery 서비스 시장 성장의 원동력은 신약에 대한 수요 증가, 연구개발비용 상승, 생물의학 연구의 기술 발전입니다. 만성 질환의 확산과 암, 감염성 질환, 희귀 유전성 질환 등의 분야에서 치료 수요가 증가함에 따라 의약품 파이프라인이 확대되고 있으며, 보다 신속하고 비용 효율적인 신약 개발 프로세스가 요구되고 있습니다. 아웃소싱을 통해 제약사는 비용과 자원을 효율적으로 관리하면서 이러한 수요에 대응할 수 있습니다. 또한 유전체학, 생물정보학, AI의 발전은 연구의 새로운 길을 열었고, 서비스 제공업체는 보다 정확하고 타겟팅된 Drug Discovery 능력을 제공할 수 있게 되었습니다.

규제 이슈와 복잡한 임상시험 요건도 신약 개발 서비스 도입을 가속화하고 있습니다. 서비스 제공업체는 규제 준수를 관리하고 임상 개발 전략을 최적화할 수 있는 전문 지식을 보유하고 있기 때문입니다. 제약회사들이 국제 시장을 개척하고 신약 개발의 세계화가 진행되면서 서비스 제공업체가 현지 규제에 대한 지식과 인프라를 제공하기 때문에 시장이 더욱 활성화되고 있습니다. 제약사의 연구개발이 점점 더 복잡해지고 비용이 증가함에 따라, Drug Discovery 서비스 시장은 치료 분야 전반에 걸쳐 혁신적인 의약품 개발에 필수적인 지원을 제공함으로써 지속적으로 성장할 것으로 보입니다.

조사 대상 기업 예시(주목받는 33개 기업)

  • Albany Molecular Research Inc.
  • Charles River Laboratories International Inc.
  • Domainex
  • Eurofins Scientific SE
  • Evotec A.G.
  • GenScript Biotech Corporation
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Pharmaceutical Product Development LLC
  • Piramal Enterprises Ltd.
  • Selvita S.A.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.11.01

Global Drug Discovery Services Market to Reach US$61.1 Billion by 2030

The global market for Drug Discovery Services estimated at US$48.6 Billion in the year 2023, is expected to reach US$61.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Medicinal Chemistry Services, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$31.6 Billion by the end of the analysis period. Growth in the Biology Services segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.9 Billion While China is Forecast to Grow at 6.9% CAGR

The Drug Discovery Services market in the U.S. is estimated at US$12.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Drug Discovery Services Market – Key Trends & Drivers Summarized

How Are Drug Discovery Services Accelerating Pharmaceutical R&D?

Drug discovery services are transforming pharmaceutical research and development (R&D) by enabling companies to outsource critical stages of drug development to specialized service providers, which enhances speed, efficiency, and cost-effectiveness. These service providers, often contract research organizations (CROs), offer expertise in areas like high-throughput screening, lead identification, preclinical research, and clinical trials, allowing pharmaceutical companies to focus on their core competencies while leveraging external capabilities. By outsourcing early-stage R&D, companies can quickly identify promising drug candidates and advance them to clinical trials, reducing the time required to bring new drugs to market and ultimately improving profitability.

In addition to expediting the drug development process, drug discovery services help pharmaceutical companies navigate the complexities of modern R&D, such as high costs, regulatory challenges, and advanced technological requirements. CROs provide access to cutting-edge technologies, including next-generation sequencing, proteomics, and bioinformatics, supporting data-intensive research and targeted drug development. This partnership model is particularly valuable for small- and medium-sized biotech firms, which may lack the resources to maintain large in-house R&D departments but still seek to drive innovation and compete in the market.

What Role Does Technology Play in Drug Discovery Services?

Technology plays a pivotal role in enhancing the capabilities and efficiency of drug discovery services, with advancements in artificial intelligence (AI), machine learning, bioinformatics, and high-throughput screening driving innovation. AI and machine learning algorithms allow CROs to analyze large datasets to identify potential drug candidates, predict compound interactions, and optimize lead compounds based on target specificity and efficacy. High-throughput screening technology enables the rapid testing of thousands of compounds against biological targets, helping to identify promising candidates early in the drug discovery process and accelerate progression through R&D stages.

In addition, computational modeling and simulation technologies aid in predicting the pharmacokinetic properties and potential toxicities of drug candidates before they enter clinical trials, reducing costly late-stage failures. Bioinformatics and molecular biology tools allow for the analysis of genetic and protein data, enabling more precise drug targeting. These technological innovations provide drug discovery service providers with advanced research capabilities, supporting pharmaceutical companies in their mission to deliver safer, more effective drugs to the market faster and with greater efficiency.

Why Are Pharmaceutical Companies Increasingly Relying on Drug Discovery Services?

Pharmaceutical companies are increasingly relying on drug discovery services to optimize R&D efficiency, access specialized expertise, and reduce costs associated with in-house development. The high fixed costs of maintaining R&D infrastructure, such as hiring specialized researchers and investing in laboratory equipment, make outsourcing a practical choice. Through drug discovery services, pharmaceutical companies can engage specialized expertise on-demand for each stage of development, from target identification to preclinical testing, providing them with the flexibility to adjust R&D resources according to project needs and market demands.

Moreover, drug discovery service providers offer expertise in niche areas like oncology, immunology, and central nervous system disorders, which helps pharmaceutical companies access innovative research methods and insights. These providers often stay updated with regulatory guidelines, supporting companies in navigating clinical trial requirements and compliance regulations efficiently. By outsourcing to specialized service providers, companies can manage risk better, accelerate time-to-market, and focus on strategic priorities, making drug discovery services an invaluable component of modern pharmaceutical R&D.

What Is Driving Growth in the Drug Discovery Services Market?

The growth in the drug discovery services market is driven by increasing demand for novel therapeutics, rising R&D costs, and technological advancements in biomedical research. The growing prevalence of chronic diseases and demand for treatments in areas such as oncology, infectious diseases, and rare genetic disorders have expanded the drug pipeline, necessitating faster and more cost-effective drug discovery processes. Outsourcing allows pharmaceutical companies to keep pace with this demand while managing costs and resources effectively. Additionally, advancements in genomics, bioinformatics, and AI have opened new avenues for research, enabling service providers to offer more precise and targeted drug discovery capabilities.

Regulatory challenges and complex clinical trial requirements have also accelerated the adoption of drug discovery services, as service providers possess the expertise to manage regulatory compliance and optimize clinical development strategies. The globalization of drug discovery, with pharmaceutical companies exploring international markets, has further fueled the market, as service providers bring regional regulatory knowledge and infrastructure. As pharmaceutical R&D becomes more complex and costly, the drug discovery services market is poised for continued growth, providing essential support for innovative drug development across therapeutic areas.

Select Competitors (Total 33 Featured) -

  • Albany Molecular Research Inc.
  • Charles River Laboratories International Inc.
  • Domainex
  • Eurofins Scientific SE
  • Evotec A.G.
  • GenScript Biotech Corporation
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Pharmaceutical Product Development LLC
  • Piramal Enterprises Ltd.
  • Selvita S.A.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Drug Discovery Services - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Focus on Innovation in Drug Discovery Drives Demand for Specialized Drug Discovery Service Providers
    • Increasing Use of AI and Machine Learning in Drug Discovery Services to Expedite Target Identification and Lead Optimization
    • Expansion of Precision Medicine and Personalized Therapies Supports Growth in Customized Drug Discovery Services
    • Rising Investment in Biologics and Small Molecule Discovery Expands Market for High-Precision Discovery Services
    • Growing Prevalence of Cancer and Autoimmune Diseases Drives Demand for Oncology-Focused Drug Discovery Services
    • Advancements in Genomics and Proteomics Fuel Demand for Target Discovery and Validation Services
    • Rising Use of High-Throughput Screening in Drug Discovery Supports Growth in Screening Services Market
    • Increased Focus on Reducing Drug Development Timelines Fuels Demand for Efficient Drug Discovery Services
    • Growing Interest in Translational Research and Biomarker Discovery Supports Demand for Early-Stage Services
    • Increased Use of Bioinformatics and Computational Modeling in Drug Discovery Services Enhances Precision in Discovery
    • Emerging Role of CRISPR and Gene Editing Technologies Expands Market for Advanced Drug Discovery Services
    • Rising Demand for Novel Drug Targets in Neurology and Psychiatry Expands Application of Drug Discovery Services
    • Increased Emphasis on Risk Mitigation in Drug Development Fuels Demand for Early Toxicology and Pharmacology Services
    • Expansion of Contract Research Organizations (CROs) Offering End-to-End Discovery Services Boosts Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Drug Discovery Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 3: World 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Medicinal Chemistry Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Medicinal Chemistry Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 6: World 18-Year Perspective for Medicinal Chemistry Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biology Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biology Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 9: World 18-Year Perspective for Biology Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Metabolism & Pharmacokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Drug Metabolism & Pharmacokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 12: World 18-Year Perspective for Drug Metabolism & Pharmacokinetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 15: World 18-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 18: World 18-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 21: World 18-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 24: World 18-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Infectious & Immune System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Infectious & Immune System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 27: World 18-Year Perspective for Infectious & Immune System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Digestive System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Digestive System Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 30: World 18-Year Perspective for Digestive System Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 33: World 18-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 36: World 18-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2024 & 2030
    • TABLE 37: World Drug Discovery Services Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 40: USA 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 43: USA 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 46: USA 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 49: Canada 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 52: Canada 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 55: Canada 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • JAPAN
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 58: Japan 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 61: Japan 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 64: Japan 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • CHINA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 67: China 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 70: China 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 73: China 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • EUROPE
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Drug Discovery Services by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 76: Europe 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 79: Europe 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 82: Europe 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 85: Europe 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • FRANCE
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 88: France 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 91: France 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 94: France 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • GERMANY
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 97: Germany 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 100: Germany 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 103: Germany 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 106: Italy 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 109: Italy 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 112: Italy 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • UNITED KINGDOM
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 115: UK 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 118: UK 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 121: UK 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 124: Spain 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 127: Spain 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 130: Spain 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 133: Russia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 136: Russia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 139: Russia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ASIA-PACIFIC
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Drug Discovery Services by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • AUSTRALIA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 163: Australia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 166: Australia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 169: Australia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • INDIA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 172: India 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 175: India 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 178: India 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 181: South Korea 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 184: South Korea 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 187: South Korea 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • LATIN AMERICA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Drug Discovery Services by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 199: Latin America 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 202: Latin America 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 205: Latin America 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 208: Latin America 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 211: Argentina 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 214: Argentina 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 217: Argentina 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 220: Brazil 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 223: Brazil 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 226: Brazil 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 229: Mexico 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 232: Mexico 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 235: Mexico 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • MIDDLE EAST
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Drug Discovery Services by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 247: Middle East 18-Year Perspective for Drug Discovery Services by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 250: Middle East 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 253: Middle East 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 256: Middle East 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 259: Iran 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 262: Iran 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 265: Iran 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 268: Israel 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 271: Israel 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 274: Israel 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 286: UAE 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 289: UAE 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 292: UAE 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030
  • AFRICA
    • Drug Discovery Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Drug Discovery Services by Type - Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 304: Africa 18-Year Perspective for Drug Discovery Services by Type - Percentage Breakdown of Value Sales for Medicinal Chemistry Services, Biology Services and Drug Metabolism & Pharmacokinetics for the Years 2012, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Drug Discovery Services by Therapeutic Area - Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 307: Africa 18-Year Perspective for Drug Discovery Services by Therapeutic Area - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Other Therapeutic Areas, Oncology, Neurology, Infectious & Immune System Diseases and Digestive System Diseases for the Years 2012, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Drug Discovery Services by Drug Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Drug Discovery Services by Drug Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2022 and % CAGR
    • TABLE 310: Africa 18-Year Perspective for Drug Discovery Services by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2012, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제